Royal Infirmary of Edinburgh
Edinburgh, Lothian, EH16 4SA, United Kingdom
NCT Number: NCT01770041
This observational study will assess the metabolic pathways of paracetamol that are utilised after liver resection.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Edinburgh, Lothian, EH16 4SA, United Kingdom
Paracetamol is normally metabolised by the glucuronidation and sulfation of paracetamol to non toxic end products. If paracetamol is administered in supra-therapeutic doses this pathway becomes saturated and an alternative pathway is utilised. This results in a toxic metabolite called N-acetyl-p-benzoquinone imine (NAPQI). If NAPQI is not metabolised by glutathione to cysteine and mercapturic acid, then NAPQI bind to hepatic cells resulting in necrosis and hepatotoxicity.
Therefore the investigators plan to measure the levels of the paracetamol metabolites in patient undergoing liver resection.
Patients will undergo liver resection according to their onco-surgical requirements. As part of the normal post operative care they will receive 1g paracetamol every six hours unless stated otherwise by the operating surgeon. Urinary samples will be taken for the first 4 post operative days and used for analysis of the urinary paracetamol metabolite levels.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Normal administration of paracetamol as prescribed by operating surgeon
Other names: Acetaminophen
Time frame: Post operative days 1-4
Time frame: post operative days 1-4
Time frame: day of surgery and post operative days 1 and 3
Time frame: day of surgery and post operative days 1 and 3
Time frame: Post-operative days 1-4
Time frame: Post-operative days 1-4
Time frame: Post-operative days 1-4
Time frame: Day of surgery and post-operative days 1-30
Time frame: Post-operative dyas 1-7
University of Edinburgh
Other
Observational Study Assessing Cytochrome P450 Dependant Paracetamol Metabolites Following Liver Resection.
Acronym: PETALS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07180641
Hepatectomy, Liver Metastases
View Trial DetailsNCT06980792
Digestive System Diseases, Digestive System Neoplasms
Modena, Italy
View Trial DetailsNCT02216773
Cancer, Liver Resection
London, United Kingdom
View Trial DetailsNCT02834338
Colorectal Resection, Gastric Resection
Dresden, Germany
View Trial Details